Answers are grounded in this paper and cite their sources.
Finds autoantibodies link to persistent weakness in statin users, highlighting the need for specific tests.
Statin-associated immune-mediated necrotizing myopathy (SINAM) is a rare but increasingly recognized autoimmune condition in which progressive proximal muscle weakness develops in statin-exposed patients and persists after drug discontinuation, driven by autoantibodies targeting HMG-CoA reductase. We report a 70-year-old woman who developed subacute progressive bilateral lower-extremity weakness on a background of nearly a year of asymptomatic, gradually worsening elevation of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), the standard liver enzymes, following more than three years of atorvastatin therapy. Diagnosis of anti-HMG-CoA reductase (anti-HMGCR) antibody-positive immune-mediated necrotizing myopathy (IMNM) was established by an isolated anti-HMGCR antibody level of 209 units (normal less than 20 units) in the setting of a uniformly negative standard myositis-specific antibody panel, confirming that anti-HMGCR must be requested as a separate assay. She was managed with atorvastatin discontinuation, high-dose corticosteroids, and escalation to intravenous immunoglobulin (IVIG) following biochemical relapse on steroid taper. This case highlights three teaching points: skeletal muscle as a frequently overlooked source of AST and ALT elevation in statin-treated patients, the necessity of dedicated anti-HMGCR testing when persistent post-statin myopathy is suspected, and the emerging serologic subtype-specific approach to second-line immunotherapy in IMNM.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: